The cAMP signaling pathway as a therapeutic target in lymphoid malignancies

Leukemia and Lymphoma

Volumn 37, Issue 1-2, 2000, Pages 39-51

  Lerner, Adam ^a,b   Kim, Doo Ho ^a   Lee, Richard ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

cAMP; Chronic lymphocytic leukemia; Lymphoid neoplasias; Malignancy; Signaling pathway; Therapeutic targets; Tumors

Indexed keywords

CHLORAMBUCIL; CILOMILAST; CILOSTAMIDE; CILOSTAZOL; CYCLIC AMP; DIPYRIDAMOLE; FORSKOLIN; METHYLXANTHINE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM; SCH 51866; SILDENAFIL; THEOPHYLLINE; UNCLASSIFIED DRUG; ZAPRINAST;

APOPTOSIS; B LYMPHOCYTE; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOID CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYMOCYTE;

EID: 0034053448     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009057627     Document Type: Review

References (72)

1. Dawson, D. L., B. S. Cutler, M. H. Meissner, and D. E. J. Strandness. 1998. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98:678.
2. Underwood, D., S. Bochnowicz, R. Osborn, C. Kotzer, M. Luttmann, D. Hay, P. Gorycki, S. Christensen, and T. Torphy, 1998. Anliasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. Journal of Pharmacology & Experimental Therapeutics. 287:988.
3. Goldstein, I., T. Lue, H. Padma-Nathan, R. Rosen, W. Steers, and P. Wicker. 1998. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 338:1397.
4. Daniel, V., G. Litwack, and G. M. Tompkins. 1973. Induction of cytolysis of cultured lymphoma cells by adenosine 3′:5′-cyclic monophosphate and isolation of resistant variants. Proc. Natl. Acad Sci. USA 70:76.
5. Coffino, P., H. R. Bourne, and G. M. Tomkins. 1975. Mechanism of lymphoma cell death induced by cyclic AMP. Am. J. Pathol. 81:199.
6. McConkey, D. J., S. Orrenius, and M. Jondal. 1990. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. J. Immunol. 145:1227.
7. Knox, K. A., G. D. Johnson, and J. Gordon. 1993. Distribution of cAMP in secondary follicles and its expression in B cell apoptosis and CD40-mediated survival. Int. Immunol. 5:1085.
8. Lomo, J., H. K. Blomhoff, K. Beiske, T. Stokke, and E. B. Smeland. 1995. TGF-B1 and cyclic AMP promote apoptosis in resting human B lymphocytes. J. Immunol. 154:1634.
9. Smit, M. J., and R. Iyengar. 1998. Mammalian adenylyl cyclases. Adv Sec Mess Phos Prot Res 32:1.
10. de Rooij, J., F. J. T. Zwartkruis, M. H. G. Verheijen, R. H. Cool, S. M. B. Nijman, A. Wittinghofer, and J. L. Bos. 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cAMP. Nature 396:474.
11. Nesterova, M., and Y. S. Cho-Chung. 1995. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1:528.
12. Ciardiello, F., R. Caputo, R. Bianco, V. Damiano, G. Pomatico, S. Pepe, A. R. Bianco, S. Agrawal, J. Mendelsohn, and G. Tortora. 1998. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. JNCI 90:1087.
13. Tortora, G., P. Tagliaferri, T. Clair, O. Colamonici, L. M. Neekers, R. K. Robins, and Y. S. Cho-Chung. 1988. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic and acute lymphocytic human leukemia cell lines. Blood 71:230.
14. Van Lookeren Campagne, M. M., F. V. Diaz, B. Jastorff, and R. H. Kessin. 1991. 8-chloroadenosine 3′,5′-monophosphate inhibits the growth of chinese hamster ovary and Molt 4 cells through its adenosine metabolite. Cancer Res 51:1600.
15. Han, Z., D. Chatterjee, and J. H. Wyche. 1993. Proliferation of nontransformed cells is inhibited by adenosine metabolite of but not by parenteral 8-Cl-cAMP. J Pharm Exper Therap 265:790.
16. Mentz, F., H. Merle-Beral, F. Ouaaz, and J.-L. Binet. 1995. Theophylline, a new inducer of apoptosis in B-CLL: role of cylic nucleotides. Br. J. Hematol. 90:957.
17. Mentz, F., M. D. Mossalayi, F. Ouaaz, S. Baudet, F. Issaly, S. Ktorza, M. Semichon, J.-L. Binet, and H. Merle-Beral. 1996. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood 88:2172.
18. Mentz, F., H. Merle-Beral, and A. Dalloul. 1999. Theophyl-line-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia 13:78.
19. Myers, D., M. Chandun-Langlie, L. Chelstrom, and F. Uckun. 1996. In vitro and in vivo anti-leukemic efficacy of cyclic AMP modulating agents against human leukemic B cell precursors. Leukemia and Lymphoma 22:259.
20. Hardin, J. A., D. H. Sherr, M. DeMaria, and P. A. Lopez. 1992. A simple fluorescence method for surface antigen phe-notyping of lymphocytes undergoing DNA fragmentation. J. Immunol. Methods 154:99.
21. Binet, J.-L., F. Mentz, V. Leblond, and H. Merle-Beral. 1995. Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia. Leukemia 9:2159.
22. Makower, D., U. Malik, Y. Novik, and P. Wiernik. 1999. Therapeutic efficacy of theophylline in chronic lymphocytic leukemia. Med Oncol 16:69.
23. Houslay, M. D., and G. Milligan. 1997. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci.:217.
24. Kim, D. H., and A. Lerner. 1998. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 92:2484.
25. Iannone, M. A., G. Wolberg, and T. P. Zimmerman. 1989. Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine. J Biol Chem 264:20177.
26. Epstein, P. M., S. Moraski, and R. Hachisu. 1987. Identification and characterization of Ca2+-calmodulin-sensitive cyclic nucleotide phosphodiesterase in a human lymphoblastoid cell line. Biochem. J. 243:533.
27. Epstein, P. M., J. S. Mills, C. P. Ross, S. J. Strada, E. M. Hersh, and W. J. Thompson. 1977. Increased cyclic nucleotide phosphodiesterase activity associated with proliferation and cancer in human and murine lymphoid cells. Cancer Res. 37:4016.
28. Hurwitz, R. L., K. M. Hirsch, D. J. Clark, V. N. Holcombe, and M. Y. Hurwitz. 1990. Induction of a calcium/calmodulin-dependent phosphodiesterase during PHA-stimulated lymphocyte mitogenesis. J. Biol. Chem. 265:8901.
29. Tenor, H., L. Staniciu, C. Schudt, A. Hatzelmann, A. Wendel, R. Djukanovic, M. K. Church, and J. K. Shute. 1995. Cyclic nucleotide phosphodiesterases from purified human CD4+ and CDS+ T lymphocytes. Clin Exper Aller 25:616.
30. Gantner, F., C. Gotz, V. Gekeler, C. Schudt, A. Wendel, and A. Hatzelmann. 1998. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation. Br J Pharmacol 123:1031.
31. Jiang, X., J. Li, M. Paskind, and P. M. Epstein. 1996. Inhibition of calmodulin dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc. Natl. Acad. Sci. USA 93:11236.
32. Wijkander, J., T. R. Landstrom, V. Manganiello, P. Belfrage, and E. Degerman. 1998. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology 139:219.
33. Maurice, D. H., and R. J. Haslam. 1990. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671.
34. Sheth, S. B., K. Chaganti, M. Bastepe, J. Ajuria, K. Brennan, R. Biradovolu, and R. W. Colman. 1997. Cyclic AMP phosphodiesterases in human lymphocytes. Br. Journal of Haematology 99:784.
35. Giembycz, M. A., C. J. Corrigan, J. Seybold, R. Newton, and P. J. Barnes. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CDS+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. British Journal of Pharmacology 118:1945.
36. Erdogan, S., and M. D. Houslay. 1997. Challenge of human Jurkat T cells with the adenylate cyclase activator forskolin elicits major changes in cAMP PDE expression by up-regulating PDE3 and inducing PDE4DI and PDE4D2 splice variants as well as down regulating a novel PDE4A splice variant. Biochem. J. 321:165.
37. Seybold, J., R. Newton, L. Wright, P. A. Finney, N. Suttorp, P. J. Barnes, I. M. Adcock, and M. A. Giembycz. 1998. Induction of phosphodiesterases 3A, 4A4, 4D1, 4D2 and 4D3 in Jurkat T cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor antagonists. J Biol Chem 273:20575.
38. Houslay, M. D., M. Sullivan, and G. B. Bolger. 1998. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Advances in Pharmacology 44:225.
39. Conti, M., S. C. Jin, L. Monaco, D. R. Repaske, and J. V. Swinnen. 1991. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocrin. Rev. 12:218.
40. Torphy, T. J., H. L. Zhou, and L. B. Cieslinski. 1992. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. J. Pharmacol. Exper. Ther. 263:1195.
41. Turner, C. R., C. J. Andresen, W. B. Smith, and J. W. Watson. 1994. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys. Am J Res Crit Care Med 14:1153.
42. Genain, C. P., T. Roberts, R. L. Davis, M. H. Nguyen, A. Uccelli, D. Faulds, Y. Li, J. Hedgpeth, and S. L. Hauser. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:3601.
43. Semmler, J., H. Wachtel, and S. Endres. 1993. The specific type IV PDE inhibitor rolipram suppresses tumor necrosis factor alpha production by human mononuclear cells. Int. J. Immunopharmacol. 15:409.
44. Platzer, C., C. Meisel, K. Vogt, M. Platzer, and H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol 7:517.
45. Michie, A. M., M. Lobban, T. Muller, M. M. Harnett, and M. D. Houslay. 1996. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine(EHNA) and rolipram. Cellular Signalling 8:97.
46. Baroja, M. L., L. B. Cieslinski, T. J. Torphy, R. L. Wange, and J. Madrenas. 1999. Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J Immunol 162:2016.
47. Michaeli, T., T. J. Bloom, T. Martins, K. Loughney, K. Ferguson, M. Riggs, L. Rodgers, J. A. Beavo, and M. Wigler. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 268:12925.
48. Bloom, T. J., and J. A. Beavo. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. USA 93:14188.
49. Li, L., C. Yee, and J. A. Beavo. 1999. CD3 and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848.
50. Epstein, P. M., S. J. Strada, K. Sarada, and W. J. Thompson. 1982. Catalytic and kinetic properties of purified high affin-ity cAMP phosphodiesterase from dog kidney. Arch Biochem Biophys 215:183.
51. Hebenstreit, G., K. Fellerer, K. Fichte, G. Fischer, N. Geyer, U. Meya, M. Sastre-y-Hernandez, W. Schony, M. Schratzer, W. Soukop, E. Trampitsch, S. Varosanec, E. Zawada, and R. Zochling. 1989. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 22:156.
52. Torphy, T. J., J. M. Stadel, M. Burman, L. B. Cieslinski, M. M. McLaughlin, J. R. White, and G. P. Livi. 1992. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J Biol Chem 267:1798.
53. Souness, J. E., and S. Rao. 1997. Proposal for pharmacologically distinct conformers of PDE4 cAMP phosphodiesterases. Cell Signal 9:227.
54. Barnette, M., S. Christensen, D. Essayen, D. Grous, U. Prabhakar, J. Rush, A. Kagey-Sobotka, and T. Torphy. 1998. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions. J Pharmacol and Exper Ther 284:420.
55. Dell'Acqua, M. L., and J. D. Scott. 1997. Protein Kinase A Anchoring. J. Biol. Chem. 272:12881.
56. O'Connell, J. C., J. F. McCallum, I. McPhee, J. Wakefield, E. S. Houslay, W. Wishart, G. Bolger, M. Frame, and M. D. Houslay. 1996. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem. J. 318:255.
57. Nemoz, G., C. Sette, and M. Conti. 1997. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol 51:242.
58. Sjoberg, J., M. Aguilar-Santelises, A.-M. Sjogren, E. K. Pisa, A. Ljungdahl, M. Bjorkholm, M. Jondal, H. Mellstedt, and P. Pisa. 1996. Interleukin 10 mRNA expression in B cell chronic lymphocytic leukemia inversely correlates with progression of disease. Br J Haematol 92:393.
59. Fluckiger, A.-C., I. Durand, and J. Banchereau. 1994. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 179:91.
60. Jurlander, J., C.-F. Lai, J. Tan, C.-C. Chou, C. H. Geisler, J. Schriber, L. E. Blumenson, S. K. Narula, H. Baumann, and M. A. Caligiuri. 1997. Characterization of interleukin-10 receptor expression on B cell chronic lymphocytic leukemia cells. Blood 89:4146.
61. Foa, R., M. Massaia, S. Cardona, A. Tos, A. Bianchi, C. Attisano, A. Guarini, P. di Celle, and M. Fierro. 1990. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 76:393.
62. Digel, W., M. Stefanic, W. Schoniger, C. Buck, A. Raghavachar, N. Frickhofen, H. Heimpel, and F. Porzsolt. 1989. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 73:1242.
63. Reittie, J., K. L. Yong, P. Panayiotidis, and A. V. Hoffbrand. 1996. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leukemia in & Lymphoma 22:83.
64. Eigler, A., T. F. Greten, B. Sinha, C. Hasleberger, G. W. Sullivan, and S. Endres. 1997. Endogenous adenosine curtails lipopolysaccharide-stimulated TNF synthesis. Scand. J. Immunol. 45:132.
65. Marcoz, P., A. F. Prigent, M. Lagarde, and G. Nemoz. 1993. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Mol. Pharmacol. 44:1027.
66. Jiang, X., M. Paskind, R. Weltzien, and P. M. Epstein. 1998. Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes. Cell Biochem Biophys. 28:135.
67. Loughney, K., T. R. Hill, V. A. Florio, L. Uher, G. J. Rosman, S. L. Wolda, B. A. Jones, M. L. Howard, L. M. McAllister-Lucas, W. K. Sonnenburg, S. H. Francis, J. D. Corbin, J. A. Beavo, and K. Ferguson. 1998. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 216:139.
68. Pfister, C., N. Bennett, F. Bruckert, P. Catty, A. Clerc, F. Pages, and P. Deterre. 1993. Interactions of a G-protein with its effector: transducin and cGMP phosphodiesterase in retinal rods. Cell Signal 5:235.
69. Soderling, S. H., S. J. Bayuga, and J. A. Beavo. 1998. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA 95:8991.
70. Fisher, D. A., J. F. Smith, J. S. Pillar, S. H. St. Denis, and J. B. Cheng. 1998. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273:15559.
71. Fujishige, K., J. Kotera, H. Michibata, K. Yuasa, S. Takebayashi, K. Okumura, and K. Omori. 1999. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274:18438.
72. Soderling, S. H., S. J. Bayuga, and J. A. Beavo. 1999. Isolation and characterization of a dual substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA. 96:7071.